Сакубитрил/валсартан у пациентов с умеренно сниженной или сохраненной фракцией выброса и ухудшением сердечной недостаточности

1. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-87. DOI:10.1093/cvr/cvac013
2. Хроническая сердечная недостаточность, клинические рекомендации Минздрава России, 2020 г. Режим доступа: https://cr.minzdrav.gov.ru/recomend/156_1. Ссылка активна на 07.09.2023 [Chronic heart failure, clinical recommendations of the Russian Ministry of Health, 2020. Available at: https://cr.minzdrav.gov.ru/recomend/156_1. Accessed: 07.09.2023 (in Russian)].
3. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-1032. DOI:10.1161/CIR.0000000000001063
5. Talha KM, Butler J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin Cardiol. 2022;45 Suppl. 1(Suppl. 1):S31-39. DOI:10.1002/clc.23846
6. Savarese G, Stolfo D, Sinagra G, et al. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100-16. DOI:10.1038/s41569-021-00605-5
7. Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. DOI:10.1002/ejhf.813
8. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858.
DOI:10.1016/S0140-6736(18)32279-7
9. Joseph P, Dokainish H, McCready T, et al; G-CHF Investigators. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. Am Heart J. 2020;227:56-63. DOI:10.1016/j.ahj.2020.06.002
10. Zhirov I, Safronova N, Osmolovskaya Y, et al. Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up. Cardiol Res Pract. 2019;2019:1692104. DOI:10.1155/2019/1692104
11. Shah KS, Xu H, Matsouaka RA, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70(20):2476-86. DOI:10.1016/j.jacc.2017.08.074
12. Shiga T, Suzuki A, Haruta S, et al; HIJ-HF II Investigators. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. ESC Heart Fail. 2019;6(3):475-86. DOI:10.1002/ehf2.12418
13. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med.
2015;175(6):996-1004. DOI:10.1001/jamainternmed.2015.0924
14. Tsao CW, Lyass A, Enserro D, et al. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018;6(8):678-85. DOI:10.1016/j.jchf.2018.03.006
15. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. DOI:10.15420/cfr.2016:25:2
16. Solomon SD, Vaduganathan M, Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352-61. DOI:10.1161/CIRCULATIONAHA.119.044586
17. Chioncel O, Mebazaa A, Harjola VP, et al. ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242-54. DOI:10.1002/ejhf.890
18. Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613-25. DOI:10.1002/ejhf.566
19. Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (регистр Павловской больницы). Сообщение 2. Клиническое значение и прогностическая роль некоторых параметров, определяемых при физикальном и инструментальном обследовании пациентов с декомпенсацией кровообращения. Сердечная недостаточность. 2014;15(2):67-75 [Arutyunov AG, Rylova AK, Arutyunov GP. Registry of hospitalized patients with decompensated circulation ("Pavlov’s hospital registr"). Report 2. Clinical significance and prognostic role of some parameters determined during physical and instrumental examination of patients with decompensated circulation. Heart Failure Journal. 2014;15(2):67-75 (in Russian)]. DOI:10.18087/rhfj. 2014.2.1934
20. Solomon SD, Dobson J, Pocock S, et al; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-7. DOI:10.1161/CIRCULATIONAHA.107.696906
21. Solomon SD, Zile M, Pieske B, et al; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-95. DOI:10.1016/S0140-6736(12)61227-6
22. Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-20. DOI:10.1056/NEJMoa1908655
23. Vaduganathan M, Claggett BL, Desai AS, et al. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020;75(3):245-54. DOI:10.1016/j.jacc.2019.11.003
24. Kristensen SL, Jhund PS, Køber L, et al. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2015;3(6):478-86. DOI:10.1016/j.jchf.2015.01.014
25. Cunningham JW, Vaduganathan M, Claggett BL, et al. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020;8(5):372-81. DOI:10.1016/j.jchf.2020.03.002
26. Myhre PL, Vaduganathan M, Claggett B, et al. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol.
2019;73(11):1264-72. DOI:10.1016/j.jacc.2019.01.018
27. Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-48. DOI:10.1056/NEJMoa1812851
28. Mentz RJ, Ward JH, Hernandez AF, et al. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. J Card Fail. 2023;29(6):922-30. DOI:10.1016/j.cardfail.2023.02.001
29. Mentz RJ, Ward JH, Hernandez AF, et al; PARAGLIDE-HF Investigators. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1-12. DOI:10.1016/j.jacc.2023.04.019
30. Fudim M, Khan MS, Paracha AA, et al. Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond. Circ Heart Fail. 2022;15(3):e009340. DOI:10.1161/CIRCHEARTFAILURE.121.009340
31. Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and ­PARAGON-HF. Eur Heart J. 2023:ehad344. DOI:10.1093/eurheartj/ehad344

________________________________________________

1. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-87. DOI:10.1093/cvr/cvac013
2. Chronic heart failure, clinical recommendations of the Russian Ministry of Health, 2020. Available at: https://cr.minzdrav.gov.ru/recomend/156_1. Accessed: 07.09.2023 (in Russian).
3. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368
4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-1032. DOI:10.1161/CIR.0000000000001063
5. Talha KM, Butler J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin Cardiol. 2022;45 Suppl. 1(Suppl. 1):S31-39. DOI:10.1002/clc.23846
6. Savarese G, Stolfo D, Sinagra G, et al. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100-16. DOI:10.1038/s41569-021-00605-5
7. Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. DOI:10.1002/ejhf.813
8. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858.
DOI:10.1016/S0140-6736(18)32279-7
9. Joseph P, Dokainish H, McCready T, et al; G-CHF Investigators. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. Am Heart J. 2020;227:56-63. DOI:10.1016/j.ahj.2020.06.002
10. Zhirov I, Safronova N, Osmolovskaya Y, et al. Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up. Cardiol Res Pract. 2019;2019:1692104. DOI:10.1155/2019/1692104
11. Shah KS, Xu H, Matsouaka RA, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017;70(20):2476-86. DOI:10.1016/j.jacc.2017.08.074
12. Shiga T, Suzuki A, Haruta S, et al; HIJ-HF II Investigators. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. ESC Heart Fail. 2019;6(3):475-86. DOI:10.1002/ehf2.12418
13. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med.
2015;175(6):996-1004. DOI:10.1001/jamainternmed.2015.0924
14. Tsao CW, Lyass A, Enserro D, et al. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018;6(8):678-85. DOI:10.1016/j.jchf.2018.03.006
15. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. DOI:10.15420/cfr.2016:25:2
16. Solomon SD, Vaduganathan M, Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352-61. DOI:10.1161/CIRCULATIONAHA.119.044586
17. Chioncel O, Mebazaa A, Harjola VP, et al. ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242-54. DOI:10.1002/ejhf.890
18. Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18:613-25. DOI:10.1002/ejhf.566
19. Arutyunov AG, Rylova AK, Arutyunov GP. Registry of hospitalized patients with decompensated circulation ("Pavlov’s hospital registr"). Report 2. Clinical significance and prognostic role of some parameters determined during physical and instrumental examination of patients with decompensated circulation. Heart Failure Journal. 2014;15(2):67-75 (in Russian). DOI:10.18087/rhfj. 2014.2.1934
20. Solomon SD, Dobson J, Pocock S, et al; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-7. DOI:10.1161/CIRCULATIONAHA.107.696906
21. Solomon SD, Zile M, Pieske B, et al; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380(9851):1387-95. DOI:10.1016/S0140-6736(12)61227-6
22. Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-20. DOI:10.1056/NEJMoa1908655
23. Vaduganathan M, Claggett BL, Desai AS, et al. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020;75(3):245-54. DOI:10.1016/j.jacc.2019.11.003
24. Kristensen SL, Jhund PS, Køber L, et al. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2015;3(6):478-86. DOI:10.1016/j.jchf.2015.01.014
25. Cunningham JW, Vaduganathan M, Claggett BL, et al. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020;8(5):372-81. DOI:10.1016/j.jchf.2020.03.002
26. Myhre PL, Vaduganathan M, Claggett B, et al. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol.
2019;73(11):1264-72. DOI:10.1016/j.jacc.2019.01.018
27. Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-48. DOI:10.1056/NEJMoa1812851
28. Mentz RJ, Ward JH, Hernandez AF, et al. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. J Card Fail. 2023;29(6):922-30. DOI:10.1016/j.cardfail.2023.02.001
29. Mentz RJ, Ward JH, Hernandez AF, et al; PARAGLIDE-HF Investigators. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1-12. DOI:10.1016/j.jacc.2023.04.019
30. Fudim M, Khan MS, Paracha AA, et al. Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond. Circ Heart Fail. 2022;15(3):e009340. DOI:10.1161/CIRCHEARTFAILURE.121.009340
31. Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and ­PARAGON-HF. Eur Heart J. 2023:ehad344. DOI:10.1093/eurheartj/ehad344

И.В. Жиров*^1,2, Н.В. Сафронова¹, С.Н. Терещенко<sup>1 

1</sup>ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия;
²ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*izhirov@mail.ru

________________________________________________

Igor V. Zhirov*^1,2, Natalia V. Safronova¹, Sergey N. Tereshchenko<sup>1

1</sup>Chazov National Medical Research Center of Cardiology, Moscow, Russia;
²Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*izhirov@mail.ru